Navigation Links
Relsys International Announces the Release of the Argus Safety(TM) Suite 5.0
Date:3/18/2009

IRVINE, Calif., March 18 /PRNewswire/ -- Relsys International today announced the release of the Argus Safety Suite 5.0, the new standard in global Drug Safety & Risk Management systems. The Argus Safety Suite 5.0 is a full stack release.

Argus Safety 5.0 features important productivity and usability enhancements to the most widely used adverse events management system in the world. It also features ongoing performance enhancements to the highly stable and efficient Argus database, ensuring that pharma companies can rapidly process and manage all of their reporting obligations.

Argus Perceptive 5.0 is a leading risk management system, pioneering the Structured Signal Management (SSM) approach. Argus Perceptive 5.0 enables powerful risk assessments with greater data accuracy, ensuring that medical reviewers get advanced notice of signals and potentially leading to earlier risk identification. While adhering to the Structured Signal Management approach, pharma companies ensure that their surveillance teams follow the signal and risk management process according to company-defined SOPs within an integrated environment.

Bruce Palsulich, Chief Innovation & Strategy Officer at Relsys, commented, "Increasing regulatory scrutiny and greater physician/consumer awareness have led directly to a record number of adverse events reported to regulators. In fact, in the first quarter of 2008, the FDA received a record number of adverse event reports, 82% of which originated from manufacturers. Pharma companies are struggling to meet this burden and are increasingly looking to commercial drug safety databases to help manage their regulatory requirements. I believe this is exactly why more than 1 out of every 3 of the Top 100 pharma have selected Argus Safety from Relsys to manage their pharmacovigilance obligations." Palsulich continued, "Furthermore, pharma is learning that signal detection tools by
'/>"/>

SOURCE Relsys International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Relsys International Launches the Pharmacovigilance Integrated Services Offering and Significantly Expands Project Delivery Capabilities
2. Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
3. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
4. Irish-Owned Heritage Casket Company Strikes Multi-Million-Dollar Partnership Deal With Pennsylvanias Matthews International
5. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
6. Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings
7. Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2
8. Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City
9. Photos: Children International Opens Center to Help Poor Children in India
10. Business Becomes Affiliate Member of International Trade Association
11. Olympus Acquires Holopack International Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 1Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 2Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13865 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3
Other Medicine Technology:Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5